Medical Device Registration in India with CDSCO: A Complete Step-by-Step Guide for Manufacturers, Importers, and Foreign Companies

Introduction

For any manufacturer, importer, or foreign company planning to sell, import, distribute, or market a medical device in India, medical device registration in India under the regulatory framework administered by the Central Drugs Standard Control Organization (CDSCO) is the foundational compliance exercise. CDSCO, operating under the Drug Controller General of India (DCGI), is the national regulatory authority for medical devices, in-vitro diagnostics (IVDs), pharmaceuticals, and cosmetics.

The framework governing CDSCO registration in India is anchored in the Medical Devices Rules, 2017, with substantial amendments and updates issued through 2024 and 2025 that have materially expanded the scope of mandatory registration. The 2024-2025 update cycle has been particularly consequential. Since 1 October 2023, all Class C and Class D medical devices (high and moderate-high risk) must hold a valid CDSCO licence, even those previously categorised as "non-notified".

In 2025, CDSCO issued final risk-classification lists for Interventional Radiology and Radiotherapy devices, and in October 2025 issued a major directive reaffirming the role of the Central Licensing Authority (CLA) in classifying Class A, Class B, and IVD devices before State Licensing Authorities (SLA) can grant manufacturing licences.

CDSCO also exempted Class A Non-Sterile, Non-Measuring (NSNM) devices from mandatory licensing in the same window. Medical device compliance in India has, as a result, become both more rigorous and more nuanced, with the right pathway depending precisely on device class, sterility, measurement function, manufacturing vs import status, and target market.

Drawing on IMARC Engineering's experience supporting medical device manufacturers, importers, and foreign companies with CDSCO medical device approval, dossier preparation, technical-file readiness, and end-to-end regulatory advisory across multiple device categories, this guide lays out a structured, step-by-step approach to medical device registration in 2026 India.

You will find a clear view on why CDSCO compliance matters, the Medical Devices Rules 2017 framework, the four-tier risk classification, a step-by-step registration process for domestic manufacturers, separate guidance for foreign manufacturers and importers, the document set, common pitfalls, a checklist, and a frequently-asked-questions section. The objective is to make CDSCO registration practical and predictable for medical-device manufacturers, importers, and global companies entering the Indian market.

Table of Contents

• Introduction
• Why CDSCO Registration Matters in 2026
• The Medical Devices Rules 2017 Framework
• Risk Classification - Class A, B, C, and D
• Step-by-Step CDSCO Registration Process for Indian Manufacturers
• CDSCO Registration for Foreign Manufacturers and Importers
• Documents Required for CDSCO Registration
• Common Mistakes and How to Avoid Them
• CDSCO Registration Checklist
• How to Choose a CDSCO Consultant
• Conclusion

1. Why CDSCO Registration Matters in 2026

Understanding why CDSCO registration in India has become so material in 2026 starts with five structural drivers that have raised the regulatory, commercial, and reputational stakes.

1.1 The Regulatory Net Has Closed Around Previously Non-Notified Devices

Until recently, large categories of medical devices operated as "non-notified", outside formal CDSCO licensing. That gap has closed sharply. Since 1 October 2023, every Class C and Class D device sold or imported in India must hold a valid CDSCO licence, including devices that were previously non-notified. In 2025, CDSCO issued final risk-classification lists for Interventional Radiology and Radiotherapy devices, formally bringing more high-value hospital-equipment categories into mandatory licensing.

The structural direction is clear: the mandatory-licensing perimeter is expanding annually, and manufacturers or importers operating in previously-unregulated categories should expect their products to be formally classified and licensed within the next 1-3 years.

1.2 Legal Consequences Are Substantial

Operating without a valid CDSCO licence after a device has been brought into mandatory licensing is a regulatory violation under the Medical Devices Rules 2017 and the parent Drugs and Cosmetics Act, 1940. Consequences include penalty proceedings, seizure of stock, import detention at port, restraint on sale and distribution, and reputational damage that affects future regulatory submissions.

For Class C and Class D devices specifically, where the 1 October 2023 deadline has already passed, the regulatory exposure is immediate. Manufacturers and importers in any device category should audit their current licensing status against the most recent CDSCO classification lists at least annually.

1.3 Commercial and Procurement Gating

CDSCO registration has become a commercial gating document. Major Indian hospitals, government health procurement (CGHS, ESIC, state procurement, central PSU buyers), insurance reimbursement frameworks, and large B2B distributors all require evidence of valid CDSCO licensing as a default qualification. Customs clearance for imported devices requires the relevant import licence (Form MD-15) for notified devices. Even where regulatory enforcement is variable, the commercial enforcement is consistent, unregistered devices face progressively narrower commercial channels even before formal regulatory action.

1.4 The Digital Workflow Has Compressed Timelines but Raised Documentation Standards

CDSCO operates the SUGAM portal (Medical Devices Online Portal) as the primary submission interface for applications, queries, fee payments, and approvals. The digital workflow has materially compressed cycle times and added transparency, but it has also raised the documentation bar - incomplete digital submissions are flagged automatically rather than corrected informally. Several 2025 enhancements (Neutral Code for Export, auto-generated compliance certificates for licensed entities, In-Country Performance Evaluation requirements for new Class B-D IVDs) further raised the documentation discipline expectations.

1.5 Global Standards Convergence Has Raised the Baseline

India's medical-device framework has progressively aligned with global standards, ISO 13485 (quality management systems for medical devices) is the de facto baseline expectation for manufacturers; the four-tier A/B/C/D risk classification mirrors GHTF / IMDRF conventions; clinical evaluation requirements for high-risk devices align with international expectations.

The harmonisation reduces duplication for global manufacturers but raises the rigor expected from purely-domestic players. For both groups, the path of least resistance is to build to global standards rather than to minimum Indian requirements, the difference is modest, the regulatory benefit is substantial, and the export optionality is meaningful.

2. The Medical Devices Rules 2017 Framework

Effective regulatory compliance medical devices in India starts with a clear understanding of the legal architecture. The Medical Devices Rules, 2017 (MDR 2017), notified under the Drugs and Cosmetics Act, 1940, came into force on 1 January 2018 and replaced the earlier ad-hoc regulation of medical devices under the parent Act with a structured framework aligned to global conventions.

2.1 Regulatory Architecture

Authority	Role	Scope
Drug Controller General of India (DCGI)	Apex national regulator	Overall direction of CDSCO and medical-device policy
Central Licensing Authority (CLA)	Central regulator	Imports, Class C and D devices, all IVDs, classification of unlisted devices
State Licensing Authority (SLA)	State-level regulator	Manufacturing licences for Class A and Class B devices
CDSCO Sub Zonal / Zonal / Port Offices	Regional offices	Inspections, sample testing, port clearance
Notified bodies	Audit and inspection bodies	Manufacturing-site audits for Class A and B (designated by CDSCO)

2.2 What the Rules Cover

MDR 2017 covers the full lifecycle of a medical device in India: classification by risk (Class A, B, C, D); registration / licensing for manufacture, import, sale, and distribution; clinical investigations and clinical performance evaluations for higher-risk devices; manufacturing-site requirements aligned to ISO 13485; labelling, packaging, and instructions for use; pharmacovigilance and post-market surveillance (Materiovigilance Programme of India - MvPI); product quality and adverse-event reporting; and recall, withdrawal, and import-port procedures. The rules apply to physical medical devices and to in-vitro diagnostics (IVDs), with category-specific provisions for software as a medical device (SaMD) and combination products.

2.3 The October 2025 Directive - Centralised Classification First

The October 2025 CDSCO directive reaffirmed the mandatory role of the Central Licensing Authority in classifying devices before any State Licensing Authority can grant a manufacturing licence for Class A or Class B devices, including IVDs. The practical implication: if a device is not on the published classification list, the applicant must first obtain a risk-based classification from the CLA, and only then can apply to the SLA for the relevant manufacturing licence.

Skipping CLA classification - which previously happened informally in some states - now risks rejection of SLA applications. This procedural tightening adds 4-8 weeks for first-time classification but materially reduces downstream rework.

2.4 The Class A NSNM Exemption

In the same window, CDSCO provided a specific exemption: Class A Non-Sterile, Non-Measuring (NSNM) devices are now exempt from mandatory licensing requirements. The exemption recognises that the lowest-risk category of devices does not justify the full licensing burden, releasing many small Indian manufacturers from licence requirements while preserving CDSCO's oversight of higher-risk categories. Manufacturers in Class A should verify whether their specific products fall into the NSNM exemption or remain within the licensing perimeter.

2.5 Perpetual Licences and Retention Fees

Under the current MDR 2017 framework, manufacturing and import licences are issued as perpetual licences - they do not expire on a fixed annual or biennial cycle. However, the licensee must pay retention fees every five years to maintain validity, and ongoing compliance (including timely reporting, post-market surveillance, and regulator audit cooperation) must be maintained.

Failure to pay retention fees or maintain compliance can result in licence suspension or cancellation. The perpetual-with-retention model reduces renewal-cycle friction but requires named ownership of the five-year retention calendar.

3. Risk Classification - Class A, B, C, and D

The four-tier risk classification is the foundation of the entire MDR 2017 framework, it determines the licensing authority (CLA vs SLA), the documentation burden, the clinical-evidence expectations, the fees, the timeline, and the post-market surveillance obligations. Understanding Class A B C D medical device licensing under MDR 2017 is the first substantive task in any registration project.

3.1 The Four Risk Classes

Class	Risk Level	Typical Examples	Licensing Authority
Class A	Low risk	Thermometers, stethoscopes, surgical dressings, non-sterile examination gloves	SLA (manufacturer); CLA (import)
Class B	Low-moderate risk	Hypodermic needles, suction equipment, hearing aids, surgical drapes	SLA (manufacturer); CLA (import)
Class C	Moderate-high risk	Lung ventilators, infusion pumps, bone fixation plates, anaesthesia equipment	CLA (manufacturer and import)
Class D	High risk	Heart valves, implantable defibrillators, pacemakers, intraocular lenses	CLA (manufacturer and import)

3.2 The Classification Rules

Classification under the Medical Devices Rules (MDR), 2017 is based on factors such as invasiveness, duration of body contact, whether the device is active or non-active, and whether it is used in critical areas such as the central circulatory or nervous system. Devices incorporating drugs, blood derivatives, or those that administer energy or substances to the body may also fall into higher-risk categories.

For IVDs, classification follows separate rules based on intended use, target analyte, and the potential impact of an incorrect result. Applicants should always verify classification against the latest CDSCO classification database and recently notified device lists before filing an application.

3.3 Clinical Evidence Requirements by Class

Clinical evidence requirements increase with device risk classification. Class A devices typically rely on published literature and equivalence data, while Class B devices may require a formal clinical evaluation supported by literature and post-market evidence. Class C and D devices generally require more extensive clinical data to demonstrate safety and performance.

For higher-risk devices, evidence may come from clinical investigations conducted under MDR 2017 or from demonstrating substantial equivalence to an approved predicate device. For new Class B, C, and D IVDs, In-Country Performance Evaluation in India is typically required regardless of approvals obtained in other jurisdictions.

3.4 Sterility, Measurement, and the NSNM Sub-Class

Within Class A, the sterility and measurement attributes create important sub-classifications. Class A Sterile devices (sterile surgical dressings, sterile syringes for single use) and Class A Measuring devices (devices with a measurement function affecting clinical decision-making) require full licensing.

Class A Non-Sterile, Non-Measuring (NSNM) devices now fall under the CDSCO exemption announced in October 2025. Manufacturers should map each specific product variant against these attributes - a single product family may have some variants that require licensing and others that fall under the NSNM exemption.

3.5 Notified vs Non-Notified Status

Historically, only devices on CDSCO's notified list required licensing. The post-2020 regulatory direction has been to progressively move non-notified devices into the notified category. The 1 October 2023 deadline brought all Class C and D devices into the mandatory licensing perimeter. The 2024-2025 classification notifications continued this expansion. For applicants, the practical implication is to verify current notification status against the latest CDSCO publications, not against older lists - the answer changes regularly.

4. Step-by-Step CDSCO Registration Process for Indian Manufacturers

For Indian manufacturers, the practical step-by-step CDSCO registration process for manufacturers unfolds across eight sequential stages. The full medical device registration timeline in India CDSCO typically runs 6-9 months for Class A and B devices, and 9-15 months for Class C and D devices, depending on documentation completeness, clinical-evidence requirements, and audit scheduling.

Stage	Activity
1. Classification verification	Confirm device class, NSNM status, notified status
2. ISO 13485 and quality system readiness	Achieve ISO 13485 certification; set up QMS
3. Device Master File and Plant Master File	Compile DMF and PMF per MDR Schedule II
4. Clinical evidence package	Literature review, predicate equivalence, or clinical investigation
5. SUGAM portal application	File Form MD-3 / MD-7 / MD-9 / MD-10 with documents and fees
6. Application review and queries	CDSCO / SLA review; respond to deficiency notices
7. Site audit and inspection	Manufacturing facility audit by Notified Body / CDSCO
8. Licence grant	Form MD-5 / MD-9 / MD-13 issued; product placed on market

 

4.1 Stage 1 - Device Classification Verification

Confirm the device's risk class (A, B, C, or D) against the latest CDSCO classification database, recently-notified classification lists (2024-2025 publications including Interventional Radiology and Radiotherapy lists), and the First Schedule of MDR 2017. Verify whether the device falls into the Class A NSNM exemption.

Where the device is not on any published list, file a classification request with the CLA - this is now mandatory before any SLA licensing application following the October 2025 directive. The output of this stage is a written classification confirmation that drives every downstream document and submission.

4.2 Stage 2 - ISO 13485 and Quality Management System Readiness

Establish or verify ISO 13485:2016 certification from an accredited certification body. The QMS must cover the full scope of devices to be manufactured, with documented procedures for design control, risk management, supplier control, production and process control, monitoring and measurement, complaint handling, CAPA, and management review.

For first-time applicants, building a compliant QMS typically takes 4-6 months including documentation, training, internal audits, and the external certification audit cycle. Manufacturers with existing ISO 13485 certification should verify the scope covers the proposed Indian product portfolio.

4.3 Stage 3 - Device Master File and Plant Master File

Compile the Device Master File (DMF) per MDR 2017 Schedule II covering: device description and specifications; intended use and indications; classification rationale; design and manufacturing information; risk management file under ISO 14971; verification and validation; biocompatibility (per ISO 10993, where applicable); sterilisation validation; stability and shelf-life; labelling and instructions for use; clinical evidence; and post-market surveillance plan.

Compile the Plant Master File (PMF) covering: manufacturing-site details; layout and process flow; equipment list; environmental controls; utilities; personnel; quality system architecture. The DMF and PMF together form the technical backbone of the application.

4.4 Stage 4 - Clinical Evidence Package

Assemble clinical evidence appropriate to the device class. For Class A devices with established predicate, literature review and predicate equivalence typically suffice. For Class B, a clinical evaluation report drawing on existing literature, post-market data, and (where appropriate) limited clinical investigation.

For Class C and D, either substantial equivalence to a previously-approved predicate device or new clinical investigation conducted in India under MDR 2017 Chapter VII (with ethics-committee approval, registered investigators, and informed-consent procedures). For new Class B-D IVDs, In-Country Performance Evaluation in India is mandatory regardless of approval in other jurisdictions.

4.5 Stage 5 - SUGAM Portal Application

File the application on the SUGAM (Medical Devices Online) portal using the relevant form: Form MD-3 (manufacturing licence application for Class A/B from SLA); Form MD-7 (manufacturing licence application for Class C/D from CLA); Form MD-9 (loan licence for contract-manufactured devices); Form MD-10 (manufacturing licence for Class A/B with loan licence); Form MD-12/MD-13 (Test Licence for clinical investigation, performance evaluation, or limited use); Form MD-14 (import licence application). Upload the DMF, PMF, ISO 13485 certificate, clinical evidence package, and supporting documents. Pay applicable fees through the portal. Submission acknowledgement is generated automatically.

4.6 Stage 6 - Application Review and Queries

CDSCO or SLA reviewers examine the application against MDR 2017 requirements. Deficiency notices are issued through the portal for missing information, inconsistencies, or technical questions. Applicants must respond within prescribed timelines - typically 45-90 days, sometimes shorter for specific queries. Multiple query rounds are common, particularly for Class C and D devices and first-time applicants. Each query round can add 4-8 weeks; structured pre-application diligence routinely reduces query rounds from 3-4 to 1-2.

4.7 Stage 7 - Site Audit and Inspection

For Class A and B devices, the manufacturing-site audit is typically conducted by a Notified Body designated by CDSCO for medical-device audits. For Class C and D devices, CDSCO inspectors typically conduct the audit. The audit verifies the manufacturing facility against MDR 2017 Schedule II, ISO 13485 conformance, the submitted PMF, and operational quality systems.

Findings categorised as critical, major, or minor must be closed within prescribed timelines before licence grant. Pre-audit internal preparation (mock audit, document readiness, training of audit-facing personnel) is the highest-leverage discipline at this stage.

4.8 Stage 8 - Licence Grant

On satisfactory review, audit closure, and fee payment, CDSCO or SLA issues the licence in the relevant form: Form MD-5; Form MD-9; Form MD-13; Form MD-15.

The licence is perpetual but requires retention-fee payment every five years. The licence specifies the device(s), site(s), and conditions; any change in scope requires a fresh or amended application. Display of the licence and ongoing compliance with MDR 2017 conditions are mandatory.

5. CDSCO Registration for Foreign Manufacturers and Importers

Foreign manufacturers cannot directly apply for CDSCO registration, the regulator requires an Indian legal entity to hold the licence and to act as the regulatory interface within India. The CDSCO import license for medical devices in India pathway is distinct from the domestic manufacturing pathway, with its own form set, documentation expectations, and timeline.

5.1 The Two Routes for Foreign Manufacturers

A foreign manufacturer has two routes to enter the Indian market: (a) establish an Indian subsidiary (Wholly Owned Subsidiary or JV) that holds the CDSCO licence directly — the route preferred where the foreign manufacturer plans long-term India operations including local manufacturing, after-sales service, and a sales team; or (b) appoint an authorized Indian agent for CDSCO registration who holds the import licence on behalf of the foreign manufacturer, the route preferred for import-only operations where the foreign manufacturer does not plan an India presence. The Indian Authorised Agent (IAA) must be an Indian entity holding a valid wholesale or manufacturing licence in India and willing to assume regulatory responsibilities under the MDR 2017.

5.2 The Import Licence Process

Securing an import license medical devices in India through the CDSCO MD-15 import license application process follows a structured workflow: (1) appoint the Indian Authorised Agent through a notarised Power of Attorney; (2) verify device classification under MDR 2017; (3) compile the regulatory dossier including the Device Master File, Plant Master File, ISO 13485 certificate (from the foreign manufacturer), Free Sale Certificate from the country of origin, clinical evidence, label artwork, and Indian-language Instructions for Use; (4) file Form MD-14 application on the SUGAM portal through the IAA; (5) respond to CDSCO queries; (6) on approval, receive Form MD-15 (the import licence); (7) commence import activities through the IAA. Total timeline typically 6-12 months for Class A and B; 9-15 months for Class C and D.

5.3 Role and Responsibilities of the Indian Authorised Agent

The Indian Authorised Agent (IAA) performs several key regulatory functions on behalf of a foreign medical device manufacturer. The IAA holds the import licence, acts as the primary point of contact with CDSCO, manages SUGAM portal communications, responds to regulatory queries, and supports customs clearance for imported products.

The IAA is also responsible for maintaining regulatory records, coordinating post-market surveillance, adverse event reporting, and product recalls where required. Because the IAA plays a central role in ongoing compliance and regulatory interactions, its expertise and responsiveness can significantly influence a manufacturer's compliance performance in India.

5.4 Documents Specific to Foreign Manufacturers

• Power of Attorney appointing the Indian Authorised Agent (notarised; apostilled or attested by the Indian embassy)
• Free Sale Certificate (FSC) / Certificate of Marketability from the country of origin
• Manufacturing licence from the country of origin (or equivalent regulatory approval)
• ISO 13485 certificate of the foreign manufacturing facility
• Device Master File and Plant Master File of the foreign facility
• Declaration of Conformity (where applicable)
• Indian-language Instructions for Use (where required by labelling rules)
• Importer / wholesaler licence held by the Indian Authorised Agent
• Test reports from accredited laboratories
• Clinical evidence appropriate to risk class

5.5 In-Country Performance Evaluation for IVDs

A critical 2024-2025 update affecting foreign IVD manufacturers: for new in-vitro diagnostic devices in Class B-D, In-Country Performance Evaluation in India is now mandatory regardless of whether the device has been approved in other countries. The evaluation is conducted in CDSCO-recognised laboratories or hospital sites using prospective testing on Indian patient populations and samples. This requirement adds 3-9 months to the typical foreign-IVD registration timeline and should be planned for at the outset of any new IVD entry into the Indian market.

6. Documents Required for CDSCO Registration

Document discipline is the single most common cause of avoidable delay in CDSCO applications. The working baseline below covers what CDSCO and SLA reviewers expect for medical device licensing in India. The exact set varies by class, applicant type (manufacturer vs importer; domestic vs foreign), and the specific licence being applied for.

6.1 Core Application Documents - All Applicants

• Completed application form (MD-3, MD-7, MD-9, MD-10, or MD-14 depending on licence type)
• Cover letter and undertaking by the applicant
• Entity documents - Certificate of Incorporation, MoA, AoA (for companies); partnership deed; KYC of authorised signatory
• ISO 13485:2016 certificate from accredited certification body (current, with appropriate scope)
• Risk classification confirmation (CDSCO database printout, classification notification, or written CLA confirmation)
• Fees challan / payment receipt

6.2 Device Master File (DMF)

• Device description, intended use, indications, contraindications
• Classification rationale per MDR 2017 First Schedule
• Design and manufacturing information
• Materials specifications and biocompatibility data per ISO 10993 (where applicable)
• Risk management file per ISO 14971
• Verification and validation reports
• Sterilisation validation (for sterile devices)
• Stability and shelf-life data
• Labels, packaging design, and instructions for use
• Clinical evaluation report or clinical investigation data
• Post-market surveillance plan

6.3 Plant Master File (PMF)

• Manufacturing-site address, location plan, layout
• Process flow diagrams
• Equipment and instrument list with capacity and calibration status
• Environmental controls (HVAC, cleanroom classification where applicable)
• Utilities (water, compressed air, electrical, gases)
• Personnel structure and qualifications
• Quality system architecture and standard operating procedures
• Cleaning, sanitisation, and contamination control
• Waste management and effluent handling

6.4 Foreign-Manufacturer-Specific Documents

• Notarised and apostilled Power of Attorney for the Indian Authorised Agent
• Free Sale Certificate / Certificate of Marketability from country of origin
• Manufacturing licence from country of origin
• Declaration of Conformity (where applicable, e.g., EU MDR conformity)
• Indian Authorised Agent's wholesale / manufacturing licence
• Indian-language Instructions for Use (where required)

6.5 Document Discipline - High-Leverage Practices

Three practices can significantly improve first-pass approval success. First, ensure complete consistency across all documents, including the device name, model number, classification, intended use, and applicant details. Even minor discrepancies between application forms, technical files, labels, and certificates can trigger regulatory queries and delays.

Second, maintain a structured document index with version control and clear mapping to MDR requirements. Finally, review the submission against the latest CDSCO guidance and regulatory notifications, as outdated documentation standards are a common cause of avoidable queries.

7. Common Mistakes and How to Avoid Them

The mistakes below are the recurring patterns we see across CDSCO engagements - and the ones most likely to add 3-12 months to the registration timeline or trigger post-grant compliance findings. Each is paired with the discipline that prevents it.

7.1 Incorrect or Stale Device Classification

The single most common error is submitting under the wrong device class - based on outdated lists, misreading of MDR 2017 First Schedule rules, or assumption of equivalence to a similar but differently-classified device. The pattern: application submitted to SLA when it should have gone to CLA (or vice versa), DMF prepared for one class when the device belongs to another, clinical evidence prepared for the wrong evidentiary standard.

7.2 Filing Without ISO 13485 in Place

Many first-time applicants file CDSCO applications expecting to obtain ISO 13485 certification "in parallel" - and discover at audit stage that the QMS gaps prevent licence grant.

7.3 Inadequate Clinical Evidence Strategy

Clinical evidence is one of the most consequential and most often-undermanaged elements of the dossier. Common patterns: relying on literature that does not match the device's intended use; assuming predicate-device equivalence without rigorous comparative analysis; underestimating the In-Country Performance Evaluation requirement for new IVDs.

7.4 Weak Indian Authorised Agent Selection (For Foreign Manufacturers)

For foreign manufacturers, the IAA is a critical regulatory partner with substantial responsibilities. Selecting an IAA based purely on lowest fees or commercial-relationship convenience routinely results in slow query responses, weak portal handling, gaps in post-market surveillance, and exposure during regulatory action.

7.5 Inconsistent Documentation

Inconsistencies across documents (device name, model number, classification, intended use, applicant details) trigger query notices and resubmissions that add weeks per round.

7.6 Under-Preparing for the Site Audit

Treating the manufacturing-site audit as a formality routinely results in critical or major findings that delay licence grant. Common gaps: documentation gaps, QMS process gaps, calibration lapses, personnel competency issues, environmental-control gaps.

7.7 Missing Post-Grant Compliance

Many manufacturers obtain CDSCO registration cleanly but then lose discipline on post-grant compliance - retention fee payments every five years, post-market surveillance, adverse event reporting under MvPI (Materiovigilance Programme of India), product-quality reviews, change control, and recall procedures. Lapses surface during CDSCO surveillance and customer audits.

8. CDSCO Registration Checklist

The checklist below consolidates the operational decision points into a structured framework that project, quality, and regulatory teams can apply directly to their next CDSCO application. It covers the practical mechanics of how to get CDSCO registration in India across the engagement lifecycle.

8.1 Pre-Application Phase

• Device classification verified against latest CDSCO database and notifications
• NSNM exemption status confirmed for Class A devices
• Notified status confirmed (especially for devices previously "non-notified")
• Licensing authority identified (CLA vs SLA per class)
• Indian Authorised Agent appointed (for foreign manufacturers)
• ISO 13485:2016 certification in place with appropriate scope
• Clinical evidence strategy defined per class requirements
• Pre-application gap analysis completed

8.2 Documentation Phase

• Device Master File compiled per MDR 2017 Schedule II
• Plant Master File compiled with site, equipment, utility, and quality system details
• Risk management file per ISO 14971 prepared
• Biocompatibility, sterilisation, and stability data assembled
• Clinical evaluation report or clinical investigation data finalised
• Labels and Instructions for Use prepared (in Indian languages where required)
• Foreign-manufacturer documents (Power of Attorney, FSC, foreign manufacturing licence, DoC) prepared and apostilled
• Document master index with consistency verification across all submissions

8.3 Submission Phase

• SUGAM portal account created (for the applicant or Indian Authorised Agent)
• Correct application form selected (MD-3, MD-7, MD-9, MD-10, MD-12, MD-13, MD-14)
• All required documents uploaded in prescribed formats
• Application fees paid and challan retained
• Submission acknowledgement received and recorded

8.4 Review, Audit, and Grant Phase

• Query notices monitored and responded to within prescribed timelines
• Internal mock audit completed 2-4 weeks before site audit
• Site audit accommodated; findings closed before licence grant
• Licence grant received (MD-5, MD-9, MD-13, or MD-15 as applicable)
• Licence displayed at manufacturing site per MDR conditions

8.5 Post-Grant Compliance Phase

• 5-year retention fee calendar set up with named owner
• Post-Market Surveillance programme operational
• Adverse Event Reporting workflow under MvPI established
• Change control procedure for product, process, or site changes
• Annual quality review and management review forums active
• Customer audit readiness maintained

9. How to Choose a CDSCO Consultant

For first-time applicants, foreign manufacturers, complex Class C/D products, or manufacturers entering new device categories, engaging a specialist CDSCO consultant in India is typically a sound investment. The selection framework below summarises what mature applicants test for, and informs the practical question of how to choose a CDSCO consultant in India that delivers durable value rather than transactional documentation support.

9.1 The Six Selection Criteria

• MDR 2017 expertise depth - track record of registrations across Class A, B, C, D, and IVDs
• Class-specific experience - particular depth on the relevant class for the device(s) being registered
• Foreign-manufacturer experience - track record with import licensing, IAA roles, and In-Country Performance Evaluation
• Sector specialism - experience with the specific therapeutic or diagnostic area
• Audit-readiness capability - hands-on experience preparing manufacturers for CDSCO/SLA site audits
• Engagement model - fixed scope, fixed fee where possible, with clear deliverables and timelines

9.2 The CDSCO Registration Consultant for Foreign Manufacturers - A Specific Note

A CDSCO registration consultant for foreign manufacturers in India plays a distinct role beyond domestic-applicant advisory, cross-border documentation discipline, Indian Authorised Agent coordination, language and labelling localisation, customs and import facilitation, and the long-term management of the regulatory relationship between the foreign principal and Indian regulators.

Foreign manufacturers should test specifically for: international regulatory experience (FDA, EU MDR, IMDRF) that translates well to CDSCO; multi-year IAA relationships and track record; bandwidth to handle ongoing PMS, AER, and re-application work over the licence lifecycle.

9.3 Red Flags to Watch

Consultants quoting substantially below market on a clearly-defined scope typically deliver templated submissions without the document discipline that drives first-pass approval. Consultants promising specific outcomes (clearance in X weeks, no queries) before doing the work are signalling either over-optimism or willingness to take shortcuts that surface as post-grant audit findings.

Conclusion

Obtaining medical device registration in India under the CDSCO framework is a structured, multi-stage process. The Medical Devices Rules, 2017, expanding licensing requirements, and recent regulatory updates have made approvals more rigorous and compliance-focused than in previous years. At the same time, digital platforms such as SUGAM and clearly defined approval pathways have improved transparency and predictability.

Three practices significantly improve approval outcomes. First, ensure accurate device classification from the outset, as it determines the applicable authority, licensing pathway, and documentation requirements. Second, complete ISO 13485 certification before submitting the CDSCO application to avoid avoidable audit-related delays.

Finally, treat post-approval compliance as an ongoing responsibility. Structured retention systems, post-market surveillance programmes, and clearly assigned compliance ownership are essential for maintaining licence validity. Whether establishing a manufacturing facility, importing devices, or expanding an existing portfolio, IMARC Engineering provides end-to-end CDSCO regulatory support.